Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 7Multiple Myeloma 7Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Sezary Syndrome 2Recurrence 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoproliferative Disorders 2Immune System Diseases 2Vascular Diseases 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Paraproteinemias 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1

Interventions

Rituximab 43Cyclophosphamide 26fludarabine 15ibrutinib 14Vincristine 11Prednisone 11Doxorubicin 11pirtobrutinib 10Bendamustine Hydrochloride 10obinutuzumab 9polatuzumab vedotin 6Inotuzumab Ozogamicin 6tocilizumab 5pembrolizumab 5glofitamab 5Gemcitabine 5zanubrutinib 4venetoclax 4ublituximab 4Lenalidomide 4Brentuximab Vedotin 4Antigens, CD19 4tazemetostat 3acalabrutinib 3Everolimus 3DTRMWXHS-12 3veltuzumab 2sepantronium 2iberdomide 2denileukin diftitox 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell × Vorinostat × Clear all
NCT00097929 2017-04-07

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Merck Sharp & Dohme LLC

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡